Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBT-401 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Bridge Biotherapeutics

Most Recent Events

  • 01 Jun 2021 According to a Bridge Biotherapeutics media release, interim data of the medium to high dose study is expected to be disclosed in the first half of 2022.
  • 15 Oct 2020 Status changed from active, no longer recruiting to discontinued.
  • 22 Sep 2020 According to a Bridge Biotherapeutics media release,the company confirmed the safety and efficacy profile of BBT-401 in the first cohort study and plans to initiate the mid to high dose cohort trials by early 2021. Additionally, the company will expand the number of trial sites to approximately 40 sites.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top